Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US biopharmaceutical firm Telik has reported that its Telcyta product has demonstrated positive results in two ongoing phase II clinical studies that are testing the effects of the drug with standard chemotherapy in the treatment of advanced non-small cell lung cancer.
Subscribe to our email newsletter
One of the trials is evaluating the triplet combination of Telcyta, a tumor-activated drug candidate, with standard doses of carboplatin and paclitaxel in 35 patients with advanced stages of the disease. 58% of the patients showed an objective tumor response rate, while the disease stabilization rate was 92%.
Responses were observed at all doses of Telcyta and at all participating sites. Phase II enrollment in the trial has been increased to confirm the interim results for future clinical studies.
The second of the trials is testing Telcyta in combination with the standard dose of cisplatin in 49 patients with the same advanced state. Objective partial responses were observed in 32% of the patients and the disease stabilization rate was 88%.
In both studies the company said the regimen was generally well tolerated.